Compare ProShares Ultra QQQ ETF (QLD) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs Twist Bioscience Corp — how do they compare? ProShares Ultra QQQ ETF trades at $87.85, while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| QLD | TWST | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $100.53 | $102.88 |
52-Week Low | $57.16 | $24.16 |
Market Cap | — | $5.97B |
Enterprise Value | — | $5.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD, the ProShares Ultra QQQ ETF, trades at $86.06, up 0.17% on the day, with a bearish technical signal driven by moving averages. The ETF, which provides 2x daily leveraged exposure to the Nasdaq-100 index, has delivered over 10,000% total return since inception, demonstrating powerful long-term compounding. Recent news highlights its role in tech-focused strategies amid a Nasdaq comeback, though leveraged structure amplifies volatility.
Outlook is mixed: technicals suggest near-term caution, but long-term growth potential remains tied to tech sector performance. Key risks include daily rebalancing effects in volatile markets and significant drawdowns, as seen historically. Investors should weigh leveraged benefits against inherent volatility and holding period considerations.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
